Lisa Tan

605 total citations · 1 hit paper
12 papers, 443 citations indexed

About

Lisa Tan is a scholar working on Immunology, Genetics and Nephrology. According to data from OpenAlex, Lisa Tan has authored 12 papers receiving a total of 443 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Immunology, 9 papers in Genetics and 4 papers in Nephrology. Recurrent topics in Lisa Tan's work include Complement system in diseases (12 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (5 papers) and Hemoglobinopathies and Related Disorders (4 papers). Lisa Tan is often cited by papers focused on Complement system in diseases (12 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (5 papers) and Hemoglobinopathies and Related Disorders (4 papers). Lisa Tan collaborates with scholars based in United Kingdom, United States and Australia. Lisa Tan's co-authors include Cedric Francois, Pascal Deschatelets, F Grossi, Carlos de Castro, Ilene C. Weitz, Jens Panse, Jeff Szer, Mohamed Hamdani, Alexander Röth and Morag Griffin and has published in prestigious journals such as New England Journal of Medicine, Blood and Molecular Immunology.

In The Last Decade

Lisa Tan

11 papers receiving 429 citations

Hit Papers

Pegcetacoplan versus Ecul... 2021 2026 2022 2024 2021 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
    2021 249 citations Peter Hillmen, Jeff Szer et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lisa Tan United Kingdom 7 373 184 177 138 59 12 443
Caterina Pascariello Italy 5 220 0.6× 93 0.5× 150 0.8× 78 0.6× 37 0.6× 13 335
Manfred Rieger Austria 5 466 1.2× 197 1.1× 260 1.5× 200 1.4× 13 0.2× 8 507
Péter Farkas Hungary 12 203 0.5× 96 0.5× 171 1.0× 107 0.8× 11 0.2× 40 427
Jean‐Marc Navenot United States 12 177 0.5× 45 0.2× 106 0.6× 53 0.4× 7 0.1× 25 370
Jérémy Hervouet France 10 346 0.9× 24 0.1× 36 0.2× 16 0.1× 6 0.1× 19 552
Matthew W. Anderson United States 7 168 0.5× 38 0.2× 66 0.4× 33 0.2× 3 0.1× 12 281
Iwona Konieczna United States 8 279 0.7× 7 0.0× 86 0.5× 36 0.3× 9 0.2× 13 501
Zonghong Shao China 12 237 0.6× 16 0.1× 209 1.2× 47 0.3× 11 0.2× 48 371
Christine Deppong United States 11 453 1.2× 22 0.1× 35 0.2× 10 0.1× 4 0.1× 14 529
Ahsen Morva France 5 251 0.7× 14 0.1× 16 0.1× 48 0.3× 3 0.1× 9 348

Countries citing papers authored by Lisa Tan

Since Specialization
Citations

This map shows the geographic impact of Lisa Tan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa Tan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa Tan more than expected).

Fields of papers citing papers by Lisa Tan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa Tan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa Tan. The network helps show where Lisa Tan may publish in the future.

Co-authorship network of co-authors of Lisa Tan

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa Tan. A scholar is included among the top collaborators of Lisa Tan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa Tan. Lisa Tan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Patriquin, Christopher J., Andrija Bogdanović, Morag Griffin, et al.. (2024). Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study. Advances in Therapy. 41(5). 2050–2069. 8 indexed citations
2.
Latour, Régis Peffault de, Morag Griffin, Richard Kelly, et al.. (2024). Hemolysis events in the phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria. Blood Advances. 8(11). 2718–2725. 7 indexed citations
3.
Wong, Raymond, Humphrey Pullon, Andrija Bogdanović, et al.. (2022). Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria. Annals of Hematology. 101(9). 1971–1986. 33 indexed citations
4.
Hillmen, Peter, Jeff Szer, Ilene C. Weitz, et al.. (2021). Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. New England Journal of Medicine. 384(11). 1028–1037. 249 indexed citations breakdown →
5.
Weitz, Howard H., Peter Hillmen, Jeff Szer, et al.. (2020). RESULTS OF THE PEGASUS PHASE 3 RANDOMIZED TRIAL DEMONSTRATING SUPERIORITY OF THE C3 INHIBITOR PEGCETACOPLAN COMPARED TO ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA. Hematology Transfusion and Cell Therapy. 42. 12–13. 2 indexed citations
6.
Castro, Carlos de, Peter Hillmen, Jeff Szer, et al.. (2020). CT-286: Results of the PEGASUS Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria. Clinical Lymphoma Myeloma & Leukemia. 20. S216–S217. 1 indexed citations
7.
Wong, Raymond, Humphrey Pullon, Jameela Sathar, et al.. (2020). C3 Inhibition with Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria: Results from the Paddock and Palomino Trials. Blood. 136(Supplement 1). 3–4. 5 indexed citations
8.
Castro, Carlos de, F Grossi, Ilene C. Weitz, et al.. (2020). C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab. American Journal of Hematology. 95(11). 1334–1343. 80 indexed citations
9.
Wong, Raymond, Humphrey Pullon, Pascal Deschatelets, et al.. (2018). Inhibition of C3 with APL-2 Results in Normalisation of Markers of Intravascular and Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). Blood. 132(Supplement 1). 2314–2314. 22 indexed citations
10.
Mehdi, Delphine El, F Grossi, Pascal Deschatelets, et al.. (2017). APL-2, a complement C3 inhibitor, may potentially reduce both intravascular and extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria. Molecular Immunology. 89. 115–115. 6 indexed citations
11.
Southworth, Thomas, Helen Richardson, Pascal Deschatelets, et al.. (2017). Repeat Measurements of Complement proteins C3a and C5a in COPD patients. PA1002–PA1002.
12.
Grossi, F, Pascal Deschatelets, Cedric Francois, et al.. (2016). APL-2, a Complement C3 Inhibitor for the Potential Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase I Data from Two Completed Studies in Healthy Volunteers. Blood. 128(22). 1251–1251. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Caterina Pascariello Breakdown of academic impact, for papers by Manfred Rieger Breakdown of academic impact, for papers by Péter Farkas Breakdown of academic impact, for papers by Jean‐Marc Navenot Breakdown of academic impact, for papers by Jérémy Hervouet Breakdown of academic impact, for papers by Matthew W. Anderson Breakdown of academic impact, for papers by Iwona Konieczna Breakdown of academic impact, for papers by Zonghong Shao Breakdown of academic impact, for papers by Christine Deppong Breakdown of academic impact, for papers by Ahsen Morva
Rankless by CCL
2026